Back to Search
Start Over
Raltegravir and etravirine are active against HIV type 1 group O.
- Source :
-
AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2009 Feb; Vol. 25 (2), pp. 225-7. - Publication Year :
- 2009
-
Abstract
- Abstract The activity of raltegravir and etravirine was assessed in vitro in HIV-1 group O isolates. Despite the presence of some natural polymorphisms associated with resistance to raltegravir (V72I, L74I, S153A, V201I, and T206S) and etravirine (G190A), both drugs showed significant antiviral activity. Subsequently, the clinical benefit was shown in an HIV-1 group O-infected individual in whom enfuvirtide was replaced by raltegravir. Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy.
- Subjects :
- Amino Acid Substitution genetics
Anti-HIV Agents therapeutic use
Drug Resistance, Viral
Female
Humans
Middle Aged
Mutation, Missense
Nitriles
Pyridazines therapeutic use
Pyrimidines
Pyrrolidinones therapeutic use
RNA, Viral blood
Raltegravir Potassium
Viral Load
Anti-HIV Agents pharmacology
HIV Infections virology
HIV-1 drug effects
Pyridazines pharmacology
Pyrrolidinones pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1931-8405
- Volume :
- 25
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- AIDS research and human retroviruses
- Publication Type :
- Academic Journal
- Accession number :
- 19239363
- Full Text :
- https://doi.org/10.1089/aid.2008.0222